Table 1: Patients characteristics and transplantation details (N = 51).
| Characteristics | Cases N = 51 (%) |
Healthy Controls (Peripheral blood donors) N = 35 (%) |
P Value |
| Gender Female Male |
24 (47%) 27 (53%) |
16 (46%) 19 (54%) |
P > 0.05 |
| Age (years) Median (range): 36 (16-69) < = 20 21-40 > 40 |
07 (14%) 22 (43%) 22 (43%) |
03 (09%) 19 (54%) 13 (37%) |
P > 0.05 |
| Diagnosis AML, ALL, ABL, MDS HL, NHL Chronic myeloid leukemia Multiple Myeloma |
31 (61%) 11 (21%) 08 (16%) 01 (02%) |
||
| Stem cell source Peripheral blood Bone marrow |
39 (77%) 12 (23%) |
||
| Intensity Conditioning Myeloablative Reduced Intensity Regimen/Nonmyeloablative |
42 (82%) 09 (18%) |
||
| GVHD prophylaxis Cyclosporine + Methotrexate Cyclosporine + Mycophenolate mofetil |
46 (90%) 05 (10%) |
||
| Days to GVHD onset (Median) Acute GVHD (range) Chronic GVHD (range) |
40 (18-70) 178 (117-270) |
||
| Acute GVHD No Yes |
28 (55%) 23 (45%) |
||
| Chronic GVHD No Yes |
20 (39%) 31 (61%) |
||
| Onset acute GVHD grade Grade I Grade II Grade III-IV |
02 (09%) 11 (48%) 10 (43%) |
||
| Onset chronic GVHD grade Mild Moderate Severe |
03 (10%) 05 (16%) 23 (74%) |
||
| Organ target at acute GVHD onset Skin only Gut only Liver only Skin + gut/liver |
01 (04%) 0 (0.0%) 0 (0.0%) 22 (96%) |
||
| Organ target at chronic GVHD onset Skin Eyes Mouth Gastrointestinal tract Liver Lung Joints or fascia |
25 (81%) 13 (42%) 26 (84%) 16 (52%) 15 (48%) 5 (16%) 4 (13%) |
AML: Acute Myeloid Leukaemia; ALL: Acute Lymphoid Leukaemia; ABL: Acute Biphenotypic Leukaemia; MDS: Myelodysplastic Syndrome; HL: Hodgkin Lymphoma; NHL: Non-Hodgkin's Lymphoma; GVHD: Graft-Versus Host Disease.